Sinopharm Group Co Ltd
HKEX:1099

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
HKEX:1099
Watchlist
Price: 19.98 HKD -0.84% Market Closed
Market Cap: 62.4B HKD
Have any thoughts about
Sinopharm Group Co Ltd?
Write Note
Sinopharm Group Co Ltd
/
Balance Sheet
/
Current Portion of Long-Term Debt

Sinopharm Group Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sinopharm Group Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Sinopharm Group Co Ltd
HKEX:1099
Current Portion of Long-Term Debt
¥76.3B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
13%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Current Portion of Long-Term Debt
¥3B
CAGR 3-Years
-8%
CAGR 5-Years
19%
CAGR 10-Years
51%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Current Portion of Long-Term Debt
¥1.6B
CAGR 3-Years
-4%
CAGR 5-Years
116%
CAGR 10-Years
3%
C
China National Medicines Corp Ltd
SSE:600511
Current Portion of Long-Term Debt
¥96.3m
CAGR 3-Years
3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Huadong Medicine Co Ltd
SZSE:000963
Current Portion of Long-Term Debt
¥562.2m
CAGR 3-Years
189%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
C
China National Accord Medicines Corp Ltd
SZSE:000028
Current Portion of Long-Term Debt
¥1B
CAGR 3-Years
9%
CAGR 5-Years
14%
CAGR 10-Years
68%
No Stocks Found

Sinopharm Group Co Ltd
Glance View

Market Cap
62.4B HKD
Industry
Health Care

Sinopharm Group Co., Ltd., a colossal force in China’s healthcare sector, navigates a complex landscape with the precision and might one might expect of a giant orchestrating a symphony. As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm operates through a broad network, ensuring that life-saving drugs and medical devices seamlessly reach hospitals, clinics, and pharmacies across the nation. Their business thrives by acting as an intermediary, efficiently bridging the gap between countless pharmaceutical manufacturers and healthcare facilities. By managing this extensive logistics and distribution network, Sinopharm not only commands an influential position in the supply chain but also shapes the very infrastructure upon which China's healthcare system depends. With a vast catalog spanning essential medicines, traditional Chinese remedies, and modern medical equipment, Sinopharm generates revenue predominantly through the distribution margins on these products. Beyond its distribution prowess, Sinopharm has strategically expanded upstream and downstream within the healthcare industry. Diversification plays a key role in its business model as the company delves into pharmaceutical manufacturing, health services, and even healthcare logistics. By owning manufacturing facilities, Sinopharm is able to create a closed-loop system for certain medications, capitalizing on the entire value chain from production to retail. Furthermore, the group expands its influence through partnerships and acquisitions, carving out a robust presence in healthcare-related services, research, and development, and retail pharmacies. This multifaceted approach enables Sinopharm to fortify its profitability, reduce dependency on external entities, and enhance its resilience amidst fluctuations in the healthcare landscape. Through its expansive reach and innovative strategy, Sinopharm cements its status as a vital player in both the national and global healthcare arenas.

Intrinsic Value
78.18 HKD
Undervaluation 74%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Sinopharm Group Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
76.3B CNY

Based on the financial report for Jun 30, 2024, Sinopharm Group Co Ltd's Current Portion of Long-Term Debt amounts to 76.3B CNY.

What is Sinopharm Group Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
13%

Over the last year, the Current Portion of Long-Term Debt growth was 0%. The average annual Current Portion of Long-Term Debt growth rates for Sinopharm Group Co Ltd have been 1% over the past three years , 3% over the past five years , and 13% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 216,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.